Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Skinny On Labeling For Orexigen’s Contrave

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech finally gains approval for its obesity agent and receives a label from FDA that, despite multiple contraindications and a boxed warning, is being looked upon favorably.

You may also be interested in...



Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Orexigen Thinks Contrave On The Verge Of Approval, Again

The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.

Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements

Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel